SUCCESS story
Nobel İlaç seeks to grow its domestic market share and achieve its targets in its foreign operations.
production of biosimilar drugs. We have been chosen as the first company and are working together with TUBITAK on this project. The first stage of the project, namely cell development, has already been completed. Next are the more advanced stages. We have made the necessary investments and have been progressing in a determined manner. This is very much in line with the general stance of our company as a champion pharmaceutical exporter with no foreign trade deficit. We consider the field of biotechnology one of the most crucial conditions for future existence and success.
Other key areas of investment for Nobel İlaç include injectables and hospital products. Why were these areas chosen?
We needed an injectables plant for the production of finished biosimilar products. The second reason for the investment is to increase our exports. We are operating in countries where injectables are highly used and plan a large number of exports to those countries. Domestically, the use of injectables in Turkey is also increasing. As the government has built city hospitals, which will enhance health tourism, the use of such products in hospitals will increase.
What are your most import export markets, and from where do you expect greater demand growth?
Currently, we have been carrying out marketing and sales operations in 20 countries through our own teams. We have been active in an extensive geographical region from Central Asia to Eastern Europe, in part through our international production facilities in Kazakhstan and Uzbekistan, which were our first steps in international expansion that started 20 years ago. These countries had potential and were open to development. These facilities not only satisfy national needs but also provide a means for exports to the neighboring regions. More recently, our newest export destination is Russia, which is especially important to us as it holds a potential equal to the combined total of all the other countries we have been active in. It is difficult to gain a place in the Russian market but our initial results are extremely promising. As future endeavors, we have been considering Africa, the Middle East, and some European countries. We have already taken the first steps in some of them.
“We have been carrying out marketing and sales operations in 20 countries through our own teams.”
What are Nobel İlaç’s most important ongoing investment plans and biggest objectives?
Our investments are ongoing in the biotechnology area, and our objective is to finish our facility and proceed with our project so that we can be in the market with these products by 2023 at the latest. Outside of that, we hope to continue to increase our domestic market share and to achieve our targets in our foreign operations. ✖
pacemakers and for insulin pumps, and we are adding more devices to the network to gather massive amounts of data.
What are the biggest challenges of overseeing such a large region?